Here is Matt Lowdon‘s weekly deals update, focusing on dealmaking and investment news across Biotech and MedTech. Congratulations to all those involved.
🔔 Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech’s gene therapy designed to reverse or prevent blindness through a potential market approval.
🔔Following the FDA clearance of its Versius robot last autumn, CMR Surgical has posted another major funding round, raising more than $200 million to bolster its U.S. commercial launch.
🔔Siemens AG is expanding its industrial software business further into the life sciences, with a $5.1 billion plan to acquire digital R&D platform developer Dotmatics.
🔔AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its programs spanning multiple therapeutic areas.
🔔Eargo, HearX merge into one OTC hearing aid firm, receive $100M boost
🔔Brookfield has struck a $1.4bn deal to buy laboratory equipment supplier Antylia Scientific from a private capital rival.
🔔Medtronic has inked a neurovascular partnership with Methinks AI, a Barcelona, Spain-based developer of programs to detect and alert providers of strokes from patient imaging scans.
🔔Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable transcription factor.
🔔MoonLake Immunotherapeutics (NASDAQ: MLTX) announce US$500 debt deal with Hercules Capital
🔔Concentra swoops in to buy Allakos Inc
🔔Boehringer Ingelheim commits $31M to ADC R&D via new Swiss facility for NBE-Therapeutics AG
🔔Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.
🔔Sangamo Therapeutics, Inc. Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the biotech’s neurotropic adeno-associated virus capsid in efforts to develop a gene therapy for a central nervous system disease.